White Paper Download

Following the study published in Alzheimer’s & Dementia in which researchers used SomaScan™ technology to predict dementia risk up to 20 years before symptoms appear, this white paper takes a broader look at how the SomaScan Assay is advancing neurology research. From uncovering protein signatures associated with Alzheimer’s pathology to identifying sex-specific risk factors and early brain changes, the SomaScan Platform is helping researchers make new discoveries in dementia biology and beyond.

What you will learn:

• How the SomaScan Assay detects low-abundance brain-related proteins in blood samples
• Key protein signatures linked to Alzheimer’s brain atrophy and vascular damage
• Why the SomaScan Assay is ideal for large-scale, diverse dementia studies